Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Multinational, Open-Label Extension Study to Evaluate the Long-Term Safety of CC-93538 in Adult and Adolescent Subjects With Eosinophilic Esophagitis

NCT04991935 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04991935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04991935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Multinational, Open-Label Extension Study to Evaluate the Long-Term Safety of CC-93538 in Adult and Adolescent Subjects With Eosinophilic Esophagitis
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
August 9, 2022
Completion date
August 14, 2025
Enrollment
367 (actual)
Sites
167

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis